Keyphrases
25(OH)D Concentration
17%
Adoptive Cell Therapy
88%
Adoptive Cell Transfer
12%
Advanced Melanoma
14%
Antitumor
12%
Autologous Tumors
19%
Autoreactive T Cells
27%
CD4+ T Cells
11%
CD8+ T
15%
CD8+ T Cells
37%
Checkpoint Inhibitors
31%
Clinical Benefit
21%
Clinical Efficacy
12%
Clinical Outcomes
13%
Clinical Response
24%
Common Genetic Variants
12%
Complete Response
14%
CYP2R1
29%
GC Gene
21%
Inhibitor Resistant
31%
Interleukin-2
16%
Ipilimumab
42%
Melanoma
78%
Metastatic Melanoma
100%
MHC Class II
12%
Microenvironment
31%
Neoantigen
18%
Neoantigen Load
21%
Neoepitope
21%
Ovarian Cancer
29%
Polyfunctional T Cells
13%
Programmed Death-ligand 1 (PD-L1)
12%
Renal Cell Carcinoma
21%
Rs10741657
11%
Rs4588
12%
Serum 25(OH)D Concentrations
27%
Serum 25-hydroxyvitamin D
21%
Serum 25OHD
15%
SNP
12%
T Cell Response
14%
T Cell Subsets
21%
T Cells
48%
Tumor
69%
Tumor Antigen
13%
Tumor Regression
23%
Tumor-infiltrating Lymphocyte Therapy
30%
Tumor-infiltrating Lymphocytes
89%
Tumor-infiltrating T Cells
15%
Tumor-specific
16%
Vitamin D Status
22%
Medicine and Dentistry
4 Iodo 2,5 Dimethoxyamphetamine
10%
Antigen Presentation
7%
Autologous Tumor Cell
5%
Cancer Cell
8%
Cancer Immunotherapy
7%
Castration Resistant Prostate Cancer
10%
Cell Therapy
35%
Clear Cell Renal Cell Carcinoma
21%
Computer Assisted Tomography
5%
CTLA-4
6%
Cytotoxic T Lymphocyte Antigen 4 Antibody
5%
Cytotoxic T-Cell
17%
Dendritic Cell
10%
Deoxyglucose
5%
Disease Exacerbation
7%
Disease Specific Survival
6%
Docetaxel
10%
Epileptic Absence
7%
Fluorine-18
10%
Fluorodeoxyglucose
10%
Frameshift Mutation
10%
Immune Response
13%
Immunity
10%
Immunotherapy
30%
Infusion
5%
Ipilimumab
31%
Malignant Neoplasm
21%
Melanoma Cell
6%
Metastatic Melanoma
66%
Neoplasm
71%
Nodular Melanoma
61%
Ovarian Cancer
21%
Point Mutation
10%
Positron Emission Tomography
10%
Progression Free Survival
6%
Recurrent Disease
10%
Sarcoidosis
10%
Specific Tumor
16%
T Cell
88%
T Cell Subset
10%
T-Cell Response
15%
T-Helper Cell
10%
Transfer Cell
13%
Tumor Antigen
9%
Tumor Infiltrating Lymphocyte
48%
Tumor Necrosis Factor
6%
Tumor Regression
25%
Immunology and Microbiology
Antigen Presentation
16%
Autoimmune Disease
7%
Behcet Disease
5%
Cancer Cell
12%
Cancer Immunotherapy
5%
Carcinoma Cell
21%
CD8
7%
Computer Assisted Tomography
5%
CTLA-4
6%
Cytotoxic T Cell
5%
Cytotoxic T Lymphocyte Antigen 4 Antibody
5%
Cytotoxic T-Cell
48%
Delayed Hypersensitivity
7%
Dendritic Cell
10%
Disease Specific Survival
10%
Frameshift Mutation
10%
Humanized Mouse
10%
Immune Escape
7%
Immune Response
21%
Immunity
10%
Immunological Memory
5%
Immunotherapy
46%
Indel Mutation
7%
Interleukin 2
13%
Ipilimumab
21%
Melanoma Cell
5%
MHC Class I
10%
MHC Class II
10%
Mouse Model
10%
Neoantigen
38%
Point Mutation
10%
Positron Emission Tomography
10%
Progression Free Survival
9%
Prostate
10%
Systemic Autoimmune Disease
10%
T Cell
94%
T-Helper Cell
11%
Transfer Cell
6%
Tumor Antigen
12%
Tumor Cell
9%
Tumor Necrosis Factor
5%
Tumor-Infiltrating Lymphocytes
48%
Ulcerative Colitis
5%
Vaccination Policy
10%
Vaccine Efficacy
7%
Whole Exome Sequencing
5%
